Cicer arietinum in the Treatment of Small Renal Stones: a Double-Blind, Randomized and Placebo-Controlled Trial

Authors

  • Azam Meyari Department of Persian Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. Department of Traditional Medicine, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Farshad Amini Behbahani Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran. Department of Persian Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Fataneh Hashem-Dabaghian Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran. Department of Persian Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Mahdi Biglarkhani Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran. Department of Persian Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran. Department of Persian Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Mohammad Ali Amir Zargar Department of Persian Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. Urology and Nephrology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Omid Sadeghpour* Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran. Department of Persian Pharmacy, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran.
Abstract:

Background and objectives: Urolithiasis is a common urological disorder. Based on the Persian medicine literatures, Cicer arietinum has a potential to dissolve renal stones. This study was designed to assess the efficacy and safety of Cicer arietinum in patients with renal stone. Methods: The extract of C. arietinum seeds was spray dried. A randomized, double blind, placebo-controlled study was conducted on 74 patients with 6-10 mm renal stones in ultrasonography. Patients were randomly assigned to take 330 mg of C. arietinum extract or placebo capsules three times a day for 30 days. Complete stone dissolution and the change in stone size during the trial was evaluated by ultrasonography. To assess the efficacy and safety of C. arietinum, blood and urine biochemical parameters were checked at baseline and after the intervention. Results: In the C. arietinum group, complete stone dissolution occurred in 9 (23.7%) patients and reduce in stone size was observed in 17 (44.7%) patients while no response to treatment was observed in placebo group. The mean stone size was reduced from 7.15 ± 1.34 mm to 4.28 ± 3.09 mm in the C. arietinum group (p<0.001) and was increased from 7.08 ± 1.09 mm to 7.15 ±1.09 mm in the placebo group (p=0.13). The changes of the stone size were significantly higher in the drug consumergroup(p˂0.001). The changes of the urinary volume and magnesium level were significantlyhigher in the treatmentgroup (P=0.04 and P=0.02, respectively). Conclusion: Cicer arietinum extract could be an effective and safe treatment option for patients with 6-10 mm renal stones.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Methoxsalen bath in the treatment of palmoplantar Eczema: A double-blind, placebo controlled clinical trial

Background: Palmoplantar eczema is a common clinical problem involving 2% of the population. There are many treatment modalities for palmoplantar eczema, each with specific local and systemic side effects. Objective: To evaluate methoxsalen bath in the treatment of palmoplantar eczema. Patients and Methods: In a randomized, double-blind, placebo controlled clinical trial, 60 patients with palmo...

full text

INJECTION OF BOTULINUM TOXIN IN THE TREATMENT OF ACHALASIA: A RANDOMIZED, DOUBLE BLIND, CONTROLLED CLINICAL TRIAL

Our aim was to evaluate the short and long term efficacy of botulinum toxin therapy in Iranian patients with achalasia. In a randomized, double blind trial, 20 patients with achalasia, referring to Imam Khomeini Hospital, received either 80 units of botulinum toxin (BT) or placebo (PL) from 1995 to 1998. Two weeks later, the response to treatment was assessed on the basis of changes in the...

full text

femicomfort in the treatment of premenstrual syndromes: a double-blind, randomized and placebo controlled trial.

objective: premenstrual syndromes (pms) affecting 20-40% of women of reproductive age. the aim of this double blind and placebo controlled trial was to investigate whether femicofort a supplement contains vitamin b6, vitamin e and evening primrose oil could relieve symptoms of pms. method: this was a randomized and double blind clinical trial. the trial was conducted between november 2009 and a...

full text

Cynara scolymus L. in Treatment of Hypercholesterolemic Type 2 Diabetic Patients: a Randomized Double-Blind Placebo-Controlled Clinical Trial

Background: Type 2 diabetes mellitus with hyperlipidemia is a common disease. Conventional anti-hyperglycemic and anti-hyperlipidemic drugs have limited efficacies and important side effects, so that alternative agents are needed. Previous studies suggest that fiber-free artichoke (Cynara scolymus L.) leaf extract may have anti-hyperglycemic and anti-hypercholesterolemic effects in hypercholest...

full text

The Efficacy of Citalopram in the Treatment of Functional Abdominal Pain in Children: A Randomized, Double-Blind, Placebo-Controlled Study

Introduction: Limited data are available on the effectiveness of antidepressants in the treatment of functional gastrointestinal disorders in children. We evaluated the effectiveness of citalopram in the treatment of childhood functional abdominal pain (FAP).   Material and Methods: Children with FAP (n=115, aged 6-18 years) received either citalopram 20 mg/day or placebo for 4 weeks. Tre...

full text

A Randomized, Double-Blind, Placebo-Controlled Trial

Results: The cumulative number of gadoliniumenhancing MRI lesions during the first 6 months were similar in the -3 fatty acids and placebo groups (median difference, 1; 95% CI, 0 to 3; P=.09). No difference in relapse rate was detected after 6 (median difference, 0; 95% CI, 0 to 0; P=.54) or 24 (median difference, 0; 95% CI, 0 to 0; P=.72) months. The proportion of patients without disability p...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 6  issue 1

pages  35- 42

publication date 2019-01-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023